NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Open in Screener

IMNM

Immunome Inc

Jul 11 • 04:00PM ET

8.64

Dollar change -0.31
Percentage change -3.46	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN MRNA NVAX SRPT NTLA CRSP PFE GILD BNTX BEAM

| Held by: VTI IWM VXF XBI IWO SCHA VTWO VHT IDNA IWC

Index	RUT	P/E	-	EPS (ttm)	-3.19	Insider Own	11.74%	Shs Outstand	86.96M	Perf Week	-2.26%
Market Cap	751.79M	Forward P/E	-	EPS next Y	-2.36	Insider Trans	3.23%	Shs Float	76.80M	Perf Month	-9.72%
Enterprise Value	439.24M	PEG	-	EPS next Q	-0.51	Inst Own	82.25%	Short Float	16.38%	Perf Quarter	39.13%
Income	-205.11M	P/S	68.72	EPS this Y	56.81%	Inst Trans	52.21%	Short Ratio	12.22	Perf Half Y	-19.70%
Sales	10.94M	P/B	2.45	EPS next Y	-9.27%	ROA	-61.93%	Short Interest	12.58M	Perf YTD	-18.64%
Book/sh	3.53	P/C	2.37	EPS next 5Y	24.72%	ROE	-69.21%	52W High	16.81 -48.60%	Perf Year	-30.88%
Cash/sh	3.65	P/FCF	-	EPS past 3/5Y	-32.63% -38.15%	ROIC	-65.76%	52W Low	5.15 67.76%	Perf 3Y	152.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	76.55%	Volatility	4.84% 5.71%	Perf 5Y	-
Dividend TTM	-	EV/Sales	40.15	EPS Y/Y TTM	57.73%	Oper. Margin	-1682.75%	ATR (14)	0.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.49	Sales Y/Y TTM	-13.76%	Profit Margin	-1875.21%	RSI (14)	47.49	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.49	EPS Q/Q	79.13%	SMA20	-2.87%	Beta	1.93	Target Price	24.50
Payout	-	Debt/Eq	0.02	Sales Q/Q	184.35%	SMA50	-0.30%	Rel Volume	0.85	Prev Close	8.95
Employees	118	LT Debt/Eq	0.02	Earnings	May 12 AMC	SMA200	-14.17%	Avg Volume	1.03M	Price	8.64
IPO	Oct 02, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.08% 273.55%	Trades		Volume	878,586	Change	-3.46%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-25	Initiated	Lake Street	Buy	$23
Nov-08-24	Initiated	Stephens	Overweight	$30
May-31-24	Initiated	Piper Sandler	Overweight	$27
Apr-30-24	Initiated	JP Morgan	Overweight	$24
Apr-15-24	Initiated	Guggenheim	Buy	$35
Jan-29-24	Initiated	Leerink Partners	Outperform	$30
Dec-19-23	Initiated	Wedbush	Outperform	$12
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight	$35

Jul-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-25 10:29AM	Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks) -8.98%
Jun-16-25 12:00PM	Immunome (IMNM) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-12-25 09:55AM	Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? (Zacks)
Jun-05-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:55AM	Loading…
May-26-25 09:55AM	Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet (Zacks)
May-22-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire) +6.82%
May-13-25 12:00PM	All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.43%
05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Immunome Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-08-25 09:55AM	Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade (Zacks)
May-02-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 06:06AM	Immunome: Transformed Pipeline Offers Multiple Catalysts (Seeking Alpha) +10.32%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks)
08:00AM	Loading…
Apr-04-25 08:00AM	Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
Mar-26-25 08:00PM	Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement (TipRanks)
Mar-19-25 05:35PM	Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immunome Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-10-25 07:41AM	Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC (Business Wire) -5.25%
Mar-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-25 08:00AM	Immunome to Present at Upcoming March Conferences (Business Wire)
Feb-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-31-25 04:01PM	Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire) -6.44%
Jan-29-25 11:11PM	Immunome Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) +12.41%
04:27PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-13-25 08:00AM	Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.28%
Jan-07-25 08:00AM	Hummingbird Bioscience Licenses Novel Antibodies to Immunome (GlobeNewswire)
Jan-02-25 06:03PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.03%
06:26PM	Loading…
Dec-02-24 06:26PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-24 01:22PM	Hedge Fund and Insider Trading News: Scott Bessent, Paloma Partners, Taula Capital Management, Immunome Inc (IMNM), AppLovin Corp (APP), and More (Insider Monkey) +16.83%
08:00AM	Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-13-24 05:15PM	Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.21%
04:05PM	Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-05-24 08:00AM	Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Nov-01-24 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.53%
Oct-30-24 08:30AM	Immunome Advances with Strategic Asset Acquisition and Agreement (TipRanks)
Oct-29-24 08:00AM	Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 (Business Wire)
Oct-18-24 08:00AM	Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium (Business Wire)
Oct-08-24 08:05AM	Immunome Appoints Roee Shahar as Executive Vice President, Commercial (Business Wire)
08:00AM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-24 07:00AM	Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (Business Wire) +8.57%
Aug-29-24 08:00AM	Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-20-24 03:26PM	Immunome Stock Sees RS Rating Jump To 91 (Investor's Business Daily) +6.36%
Aug-12-24 05:15PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.04%
04:01PM	Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 08:00AM	Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities (Business Wire) +5.67%
07:30AM	Nectin Therapeutics Licenses Novel Antibodies to Immunome (PR Newswire)
Jul-09-24 07:00AM	STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors (GlobeNewswire)
Jun-27-24 08:00AM	Immunome Appoints Phil Tsai as Chief Technical Officer (Business Wire)
May-22-24 02:05PM	Hedge Fund and Insider Trading News: David Tepper, Stanley Druckenmiller, Oaktree Capital Management, Odey Asset Management, ProFrac Holding Corp. (ACDC), Immunome Inc (IMNM), and More (Insider Monkey) +5.64%
May-21-24 07:01PM	Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares (GuruFocus.com)
May-20-24 11:14AM	Immunome Completes Purchase of Antibodies From Atreca (MT Newswires)
08:00AM	Immunome Announces Completion of Purchase of Assets from Atreca (Business Wire)
May-17-24 08:51AM	Immunome Appoints Max Rosett as CFO (MT Newswires)
08:00AM	Immunome Announces Promotion of Max Rosett to Chief Financial Officer (Business Wire)
May-14-24 01:54PM	IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.70%
09:10AM	Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Immunome Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-08-24 08:00AM	Immunome to Present at 2024 Bank of America Healthcare Conference (Business Wire)
May-02-24 08:00AM	Immunome Appoints Kinney Horn as Chief Business Officer (Business Wire)
Apr-30-24 07:29AM	--JPMorgan Starts Immunome With Overweight Rating, $24 Price Target (MT Newswires)
Apr-26-24 10:00AM	Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-25-24 08:26AM	Immunome Appoints Sandra M. Swain to Board of Directors (Business Wire)
Apr-05-24 08:00AM	Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-28-24 11:53PM	IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.41%
04:02PM	Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets (Business Wire)
Mar-26-24 08:00AM	Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala (Business Wire) +5.79%
08:00AM	Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome (GlobeNewswire)
Mar-18-24 05:44AM	Arrayjets ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies (Business Wire)
Mar-07-24 08:00AM	Immunome to Participate in the Leerink Partners Global Biopharma Conference (Business Wire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Mar-01-24 08:00AM	Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference (Business Wire) +5.17%
Feb-20-24 08:15AM	Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors (Business Wire) -10.99%
08:00AM	Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors (GlobeNewswire)
Feb-16-24 04:05PM	Immunome Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) +14.74%
Feb-13-24 10:38PM	Immunome Announces Pricing of Public Offering of Common Stock (Business Wire)
04:05PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Feb-07-24 08:34AM	Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up (Zacks) +7.83%
Feb-06-24 09:20AM	Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks (FierceBiotech.com) +36.91%
08:00AM	Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals (Business Wire)
Feb-05-24 08:00AM	Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-08-24 07:00AM	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform (Business Wire) +7.91%
Jan-04-24 08:00AM	Immunome Appoints Phil Roberts as Chief Technical Officer (Business Wire)
Jan-03-24 08:00AM	Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +7.27%
Jan-02-24 08:00AM	Immunome Appoints Carol A. Schafer to Board of Directors (Business Wire)
Dec-26-23 08:30AM	Immunome to Acquire Antibody-Related Assets and Materials from Atreca (Business Wire) +8.20%
08:30AM	Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome (GlobeNewswire)
Nov-10-23 08:00AM	Immunome to Present at the Stifel 2023 Healthcare Conference (Business Wire) -5.49%
Nov-09-23 08:00AM	Immunome Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-08-23 08:00AM	Immunome Appoints Jean-Jacques Bienaim to Board of Directors (Business Wire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-19-23 08:00AM	Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer (Business Wire)
Oct-04-23 11:00PM	Insider Buying: Immunome Inc's President and CEO Clay Siegall Acquires 169,204 Shares (GuruFocus.com)
Oct-03-23 08:00AM	Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies (Business Wire)
Aug-17-23 08:19PM	Inside the deal: How Immunome and MophImmune came to a merger agreement (American City Business Journals)
Aug-09-23 08:00AM	Immunome Reports Second Quarter 2023 Financial Results (Business Wire)
Jun-30-23 09:51AM	Immunome (IMNM) Surges on Merger Agreement With Morphimmune (Zacks)
Jun-29-23 09:00AM	Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies (PR Newswire) +30.29%

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Director	Jun 03 '25	Buy	9.38	5,000	46,900	36,415	Jun 03 09:21 PM
Higgins Jack	Chief Scientific Officer	Mar 27 '25	Option Exercise	1.35	5,200	7,020	18,729	Mar 28 05:54 PM
BIENAIME JEAN JACQUES	Director	Mar 25 '25	Buy	7.78	7,800	60,684	31,415	Mar 26 04:05 PM
SIEGALL CLAY B	President and CEO	Mar 26 '25	Buy	7.29	137,100	999,459	806,736	Mar 26 04:03 PM
BIENAIME JEAN JACQUES	Director	Mar 24 '25	Buy	8.21	7,000	57,470	23,615	Mar 25 05:18 PM
Tsai Philip	Chief Technology Officer	Mar 24 '25	Buy	8.42	12,300	103,566	33,300	Mar 25 05:15 PM
SIEGALL CLAY B	President and CEO	Jan 31 '25	Buy	7.75	150,000	1,162,500	669,636	Feb 03 09:01 PM
SIEGALL CLAY B	President and CEO	Nov 21 '24	Buy	9.54	66,057	630,263	485,693	Nov 25 08:41 AM
SIEGALL CLAY B	President and CEO	Nov 22 '24	Buy	9.78	33,943	331,918	519,636	Nov 25 08:41 AM
Lechleider Robert	Chief Medical Officer	Nov 21 '24	Buy	9.48	15,805	149,800	15,805	Nov 25 08:35 AM
Tsai Philip	Chief Technology Officer	Nov 21 '24	Buy	9.43	21,000	198,030	21,000	Nov 25 08:33 AM
Rosett Max	Chief Financial Officer	Sep 19 '24	Option Exercise	1.05	42,000	44,100	61,856	Sep 20 07:26 PM
Rosett Max	Chief Financial Officer	Sep 19 '24	Sale	16.01	14,380	230,224	47,476	Sep 20 07:26 PM
Rosett Max	Officer	Sep 19 '24	Proposed Sale	16.01	14,380	230,211		Sep 19 02:18 PM
BIENAIME JEAN JACQUES	Director	Aug 16 '24	Buy	13.94	7,000	97,608	16,615	Aug 19 09:07 PM
Higgins Jack	Chief Scientific Officer	Aug 15 '24	Option Exercise	1.35	19,524	26,357	19,524	Aug 19 09:05 PM
Higgins Jack	Chief Scientific Officer	Aug 15 '24	Sale	13.93	3,524	49,072	16,000	Aug 19 09:05 PM
Higgins Jack	Officer	Aug 15 '24	Proposed Sale	13.93	3,524	49,073		Aug 15 03:21 PM

Dollar change -0.72
Percentage change -1.22	%

BMRN Biomarin Pharmaceutical Inc daily Stock Chart

Peers: REGN VRTX SRPT NBIX ALNY BLUE IONS RARE EXEL PRTA

| Held by: IJH VTI VB VXF VBK XBI MDY IBB IJJ SPMD

Index	-	P/E	21.56	EPS (ttm)	2.69	Insider Own	1.42%	Shs Outstand	191.76M	Perf Week	1.04%
Market Cap	11.14B	Forward P/E	13.90	EPS next Y	4.18	Insider Trans	-0.43%	Shs Float	189.06M	Perf Month	1.08%
Enterprise Value	10.48B	PEG	0.65	EPS next Q	0.83	Inst Own	98.19%	Short Float	3.45%	Perf Quarter	-2.24%
Income	523.88M	P/S	3.81	EPS this Y	57.82%	Inst Trans	1.22%	Short Ratio	3.11	Perf Half Y	-14.43%
Sales	2.92B	P/B	1.92	EPS next Y	19.85%	ROA	7.47%	Short Interest	6.52M	Perf YTD	-11.61%
Book/sh	30.21	P/C	8.76	EPS next 5Y	33.31%	ROE	9.64%	52W High	94.85 -38.75%	Perf Year	-29.98%
Cash/sh	6.63	P/FCF	17.85	EPS past 3/5Y	- -	ROIC	8.20%	52W Low	52.93 9.77%	Perf 3Y	-32.76%
Dividend Est.	-	EV/EBITDA	14.60	Sales past 3/5Y	15.43% 10.98%	Gross Margin	78.25%	Volatility	2.57% 2.38%	Perf 5Y	-54.51%
Dividend TTM	-	EV/Sales	3.59	EPS Y/Y TTM	152.10%	Oper. Margin	21.44%	ATR (14)	1.48	Perf 10Y	-57.51%
Dividend Ex-Date	-	Quick Ratio	3.49	Sales Y/Y TTM	17.99%	Profit Margin	17.93%	RSI (14)	55.35	Recom	1.52
Dividend Gr. 3/5Y	- -	Current Ratio	5.52	EPS Q/Q	108.02%	SMA20	3.29%	Beta	0.18	Target Price	96.50
Payout	0.00%	Debt/Eq	0.11	Sales Q/Q	12.72%	SMA50	0.52%	Rel Volume	0.95	Prev Close	58.82
Employees	3040	LT Debt/Eq	0.10	Earnings	May 01 AMC	SMA200	-9.61%	Avg Volume	2.10M	Price	58.10
IPO	Jul 23, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	39.21% 0.88%	Trades		Volume	1,993,339	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-03-25	Resumed	Morgan Stanley	Overweight	$97
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform	$98
Nov-15-24	Initiated	Wolfe Research	Outperform	$95
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform	$79
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102
Jun-14-23	Resumed	Credit Suisse	Outperform	$120
Mar-21-23	Initiated	Bernstein	Underperform	$81
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral	$116
Jan-30-23	Initiated	BMO Capital Markets	Market Perform	$107
Jan-18-23	Initiated	Canaccord Genuity	Hold	$119

Show Previous Ratings

Jul-11-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Jul-10-25 11:26PM	Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside (Insider Monkey)
12:10PM	Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:08AM	BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma (Insider Monkey)
Jul-08-25 09:50AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock (Zacks)
08:45AM	Loading…
Jul-01-25 08:45AM	BioMarin Announces Completion of Acquisition of Inozyme (PR Newswire)
Jun-28-25 04:16AM	BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A (Insider Monkey)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Jun-26-25 04:19AM	The Top 5 Analyst Questions From BioMarin Pharmaceutical's Q1 Earnings Call (StockStory)
Jun-25-25 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Jun-24-25 09:00AM	BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress (PR Newswire)
Jun-23-25 01:36AM	Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating (Insider Monkey)
12:01AM	2 Reasons to Watch BMRN and 1 to Stay Cautious (StockStory)
Jun-20-25 05:00PM	Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders (GlobeNewswire)
05:26AM	Loading…
Jun-15-25 05:26AM	Jim Cramer on BioMarin: "I Don't Think It Works Now" (Insider Monkey)
Jun-11-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-09-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-05-25 03:06AM	Here Are All 6 Stocks I've Bought Through 5 Months of 2025 (Motley Fool)
May-28-25 11:40AM	Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? (Zacks)
May-26-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks)
09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-19-25 09:06AM	BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz (Zacks)
04:22AM	BioMarin agrees to acquire Inozyme for $270m (Pharmaceutical Technology)
May-18-25 08:17AM	BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition (Insider Monkey)
May-17-25 01:30PM	Leerink bullish on BioMarin following Inozyme deal, expects additional BD (TipRanks)
May-16-25 09:37AM	How BioMarin's $270 Million Takeover Led This Dollar Stock To A Triple-Digit Gain (Investor's Business Daily)
09:37AM	BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover (Investor's Business Daily)
08:26AM	Loading…
08:26AM	BioMarin to buy rare disease drugmaker Inozyme for $270M (BioPharma Dive)
07:30AM	BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma (PR Newswire)
06:34AM	BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress (StockStory)
May-14-25 07:48AM	BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-12-25 09:05AM	BioMarin Presents New Data for VOXZOGO (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings (PR Newswire)
May-09-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
04:41AM	BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer's Stock Picks with Huge Upside Potential (Insider Monkey)
12:37AM	1 Healthcare Stock with Competitive Advantages and 2 to Brush Off (StockStory)
May-07-25 04:11PM	BioMarin Pharmaceutical Inc. (BMRN): Among Stocks That Will Make You Rich In 3 Years (Insider Monkey)
May-06-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
May-05-25 09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
May-02-25 05:57PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
01:23PM	BioMarin's First-Quarter Earnings & Sales Beat Estimates (Zacks)
08:13AM	Q1 2025 BioMarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Biomarin Pharmaceutical Inc (BMRN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-01-25 07:30PM	BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:25PM	BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:15PM	BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates (Zacks)
04:17PM	BioMarin: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance (PR Newswire)
Apr-29-25 11:38AM	BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-27-25 01:13PM	2 Cash-Producing Stocks with Exciting Potential and 1 to Question (StockStory)
Apr-23-25 08:47PM	BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
08:44AM	Implied Volatility Surging for BioMarin Stock Options (Zacks)
Apr-21-25 10:16AM	Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store? (Zacks)
Apr-18-25 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Apr-17-25 10:00AM	Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:00AM	BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET (PR Newswire)
Apr-16-25 10:00AM	BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
09:53AM	Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last? (Zacks)
Apr-11-25 03:06AM	6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility (Motley Fool)
Apr-10-25 12:10PM	Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? (Zacks) -5.23%
08:17AM	Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength? (Zacks)
02:37AM	Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Apr-09-25 03:00PM	Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On (Zacks) +6.33%
Apr-08-25 09:56AM	Viatris to Pay $335 Million for Settlement of Opioid-Related Claims (Zacks) -5.53%
Apr-07-25 01:22PM	5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 (Zacks)
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) (Zacks)
12:00PM	What Makes BioMarin (BMRN) a New Buy Stock (Zacks)
11:40AM	BMRN vs. CSLLY: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Apr-03-25 03:37PM	BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion (Seeking Alpha)
10:14AM	BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study (Zacks)
04:54AM	BioMarins trial for phenylketonuria therapy meets primary efficacy endpoint (Clinical Trials Arena)
Apr-02-25 03:06PM	BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients (Benzinga)
09:48AM	Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
09:00AM	BioMarin Announces Positive Pivotal Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria (PR Newswire)
Mar-28-25 09:50AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock (Zacks)
Mar-27-25 10:10AM	Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
05:06AM	5 Historically Cheap Growth Stocks to Buy With Confidence in the Wake of the Nasdaq Correction (Motley Fool)
Mar-26-25 05:11AM	2 Reasons to Like BMRN (and 1 Not So Much) (StockStory)
Mar-25-25 09:18PM	Is BioMarin Pharmaceutical Inc. (BMRN) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-21-25 11:30AM	BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? (Zacks)
10:10AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
05:05AM	Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) (StockStory)
Mar-20-25 03:25PM	BioMarin Pharmaceutical (BMRN): Among Paul Singer's Latest Portfolio's Top Stock Picks (InsiderMonkey)
09:00AM	BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting (PR Newswire)
Mar-19-25 05:05AM	A Look Back at Therapeutics Stocks Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack (StockStory)
Mar-18-25 05:55AM	Is BioMarin Pharmaceutical (BMRN) the Best Biotech Stock According to Billionaires? (Insider Monkey)
Mar-17-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Mar-12-25 12:45PM	Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
09:55AM	Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to Trade (Zacks)
09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
Mar-11-25 09:01AM	1 Healthcare Stock to Target This Week and 2 to Turn Down (StockStory)
05:03AM	Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks (StockStory)
Mar-05-25 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Mar-04-25 04:03AM	Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 (StockStory)
Feb-28-25 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkhart Erin	GVP, Chief Accounting Officer	May 20 '25	Sale	59.31	1,786	105,928	14,173	May 20 05:58 PM
Burkhart Erin	Officer	May 20 '25	Proposed Sale	59.31	1,786	105,928		May 20 09:58 AM
Hubbard Cristin	EVP, Chief Commercial Officer	May 02 '25	Sale	64.92	273	17,723	32,700	May 06 05:07 PM
Hubbard Cristin	Officer	May 02 '25	Proposed Sale	64.92	273	17,723		May 02 10:05 AM
Burkhart Erin	GVP, Chief Accounting Officer	Mar 19 '25	Sale	71.52	1,295	92,618	16,955	Mar 20 07:38 PM
Burkhart Erin	Officer	Mar 19 '25	Proposed Sale	71.52	1,295	92,618		Mar 19 09:36 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 06 '25	Sale	71.28	7,034	501,355	87,655	Mar 07 04:06 PM
Guyer Charles Greg	Officer	Mar 06 '25	Proposed Sale	71.28	7,034	501,359		Mar 06 04:05 PM
Burkhart Erin	GVP, Chief Accounting Officer	Feb 24 '25	Sale	68.38	1,344	91,903	13,105	Feb 25 08:21 PM
Burkhart Erin	Officer	Feb 24 '25	Proposed Sale	68.38	1,344	91,903		Feb 24 10:26 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Nov 12 '24	Sale	66.37	5,278	350,324	68,909	Nov 14 02:44 PM
Guyer Charles Greg	Officer	Nov 12 '24	Proposed Sale	66.37	5,278	350,324		Nov 12 02:27 PM
Burkhart Erin	GVP, Chief Accounting Officer	Aug 13 '24	Sale	90.00	714	64,260	14,449	Aug 15 03:57 PM
Burkhart Erin	Officer	Aug 13 '24	Proposed Sale	90.00	714	64,260		Aug 13 11:48 AM

IMNM

Immunome Inc

BMRN

Biomarin Pharmaceutical Inc

Upgrade your FINVIZ experience